Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03524430 · ClinicalTrials.gov registry record · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
A NA study of Breast Neoplasm Female, sponsored by Rna Diagnostics.
- Recruiting
- Registry status
- NA
- Development phase
- 801
- Enrollment target
- 7
- Study locations
NCT03524430: Recruiting NA study of Breast Neoplasm Female, sponsored by Rna Diagnostics.
NCT03524430 is a NA study of Breast Neoplasm Female that is actively recruiting participants, run by Rna Diagnostics. The registered enrollment target is 801 participants, above the 80-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (901% higher). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03524430, a NA study of Breast Neoplasm Female, is actively recruiting participants, sponsored by Rna Diagnostics.
- RECRUITING
- Registry status
- NA
- Development phase
- 801 participants
- Enrollment target
- 7
- Study locations
Study Summary
The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.
Primary Outcome
(ypT0,ypN0) / (ypTis,ypN0)
Conditions Studied
Interventions
- PROCEDURE Core needle biopsy
Study Locations (7)
Other
- Sunnybrook Health Sciences Center - Toronto
- Institut de Cancerologie de Strasbourg - Strasbourg
- Universitätsklinikum Münster - Münster
- SST di Cremona Multidisciplinare di Patologia Mammaria, Italy - Cremona
- NZOZ Neuromed - Lublin
- Hospital U. 12 de Octubre - Madrid
Missouri
- Siteman Cancer Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 801 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2031-03-31 |
| Phase | NA |
What NCT03524430 shows while recruiting
NCT03524430 is an interventional study that assigns participants to a tested intervention. The registered 801 participants enrollment target is mid-sized for trials with a published cap, above the 80-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (901% higher).
The record links to 1 condition, with Breast Neoplasm Female appearing as the primary indexed condition, and to 1 intervention - of which Core needle biopsy is the first listed.
NCT03524430 lists 7 locations in 2 states (Other, Missouri).
Frequently Asked Questions
What is clinical trial NCT03524430 about?
NCT03524430 is a clinical study titled "RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy". The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.
What is the current status of trial NCT03524430?
This trial is currently recruiting. It is a NA study. The enrollment target is 801 participants. The study started on 2018-04-26. Estimated completion is 2031-03-31.
What conditions does trial NCT03524430 study?
This clinical trial studies the following conditions: Breast Neoplasm Female.
What interventions are being tested in trial NCT03524430?
The interventions under investigation include: Core needle biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03524430?
This trial is sponsored by Rna Diagnostics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03524430 being conducted?
This trial has 7 study locations across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03524430's enrollment target sits among peer trials
801 1st of 8 higher than 8 of 8 other Breast Neoplasm Female trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasm Female trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
RECRUITING · NA
-
Study on Physical Activity's Relationship With Cancer and Cognition
COMPLETED · NA
-
Web-Base App To Improve Aromatase Inhibitor Adherence
COMPLETED · NA
-
Mayo Designed Soft Tissue Ultrasound-Detectable Marker
COMPLETED · NA
-
THRIVE Breast Cancer App Study
COMPLETED · NA
-
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI